Omiganan for Eczema: A 93.5% Bacterial Reduction Was Not a 93.5% Symptom Improvement
DOCTOR’S NOTES · ECZEMA EVIDENCE
A very large percentage can be accurate yet describe the wrong outcome for a treatment claim. Omiganan research reported a striking reduction in cultured bacteria without establishing significant clinical improvement in the later trial. The number should remain attached to its laboratory endpoint.
The first study focused on one lesion
The 2020 primary phase 2 report randomized 36 people with mild-to-moderate atopic dermatitis to once-daily omiganan 1%, 2.5% or vehicle on one target lesion for 28 days. The highest concentration produced small statistical changes in local severity and morning itch. The authors questioned their clinical importance; the morning-itch change did not meet the cited meaningful-change threshold.
The later trial treated all lesions
The primary abstract in the researchers’ university record describes 80 people randomized to omiganan 1%, 1.75%, 2.5% or vehicle twice daily for 28 days on all lesions. It appeared online in 2020 and in the April 2022 issue.
| Later-trial endpoint | Finding |
|---|---|
| Cultured S. aureus, 2.5% versus vehicle | −93.5%; 95% CI −99.2 to −28.5; P=.02. |
| Microbial diversity and composition | Changes consistent with reduced dysbiosis. |
| Clinical improvement | No significant benefit established. |
What the bacterial percentage does not mean
It is not an eczema-clearance percentage, a proportion of patients who recovered or a percentage reduction in itch. Substituting any of those descriptions would change the endpoint. A laboratory measurement can show target engagement without proving patient benefit.
Biological plausibility, target engagement and clinical usefulness are separate steps. Success at one step does not remove the need to demonstrate the next. The later clinical result also prevents an early small local signal from being presented as settled evidence.
Why the studies cannot be pooled by eye
They differed in treated area, application frequency, concentrations and population size. A target-lesion response is not interchangeable with an all-lesion regimen. It is reasonable to investigate an early signal further; it is misleading to retain only the favorable early observation and omit the later clinical comparison.
A better question for a microbiome claim
Ask what improved for patients, against which comparator and over what period. If the answer concerns only bacteria or a biomarker, keep it in that category. Avoid escalating antimicrobial products simply to make a laboratory concept sound complete. The studies do not show that a cosmetic moisturizer reproduces omiganan’s microbiological effect.
AAD eczema guidance provides the broader care reference. Persistent symptoms deserve a review of the diagnosis and plan rather than an assumption that a microbiome reading explains the entire condition.
Why a large moisturizer cohort cannot isolate one ingredient’s effect
Where moisture care fits
Dr. Arsy Moisturizer #003, 4 oz (120 g) is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. It does not treat, cure or prevent eczema and was not the intervention in these studies. This research does not establish pediatric efficacy or infant suitability for #003; ask a child’s clinician about an appropriate moisturizer.
Continue with a related question
- How to Read an Eczema Study Without Getting Misled by Percentages
- Your Eczema Itch Score and Your Rash Score Can Tell Different Stories
- What Is SCORAD? Understanding an Eczema Severity Score
Prepared by the Dr. Arsy editorial team. Sources checked November 9, 2026. Educational content does not diagnose an individual or imply independent medical review. Cited researchers and institutions do not endorse #003. Image is an AI-created editorial product illustration, not a patient photograph or clinical result.